Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Short Interest Update

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 45,625 shares, a growth of 58.3% from the August 31st total of 28,830 shares. Currently, 1.5% of the shares of the stock are sold short. Based on an average trading volume of 33,064 shares, the short-interest ratio is presently 1.4 days.

Eloxx Pharmaceuticals Stock Down 0.7%

Shares of NASDAQ:ELOX traded down $0.11 on Wednesday, hitting $15.31. The stock had a trading volume of 14,329 shares, compared to its average volume of 26,908. The company has a 50 day moving average of $16.53. Eloxx Pharmaceuticals has a twelve month low of $8.20 and a twelve month high of $23.40. The company has a market cap of $61.85 million, a P/E ratio of -9.94 and a beta of -1,862.26.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last announced its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ELOX shares. Guggenheim reissued a “buy” rating and issued a $43.00 target price on shares of Eloxx Pharmaceuticals in a research note on Monday, August 24th. Lifesci Capital initiated coverage on shares of Eloxx Pharmaceuticals in a research note on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 price target for the company. Weiss Ratings started coverage on Eloxx Pharmaceuticals in a research note on Friday, August 14th. They issued a “sell (d)” rating on the stock. Lucid Cap Mkts raised Eloxx Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 20th. Finally, Leerink Partners set a $32.00 target price on Eloxx Pharmaceuticals and gave the stock an “outperform” rating in a research report on Friday, September 18th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Eloxx Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $38.33.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nonsense mutations, which can prevent cells from producing functional proteins. The company’s research platform centered on ribosome modulation, an approach intended to encourage cells to read through certain premature stop signals in genetic instructions.

Its lead product candidate, ELX-02, was an investigational small-molecule therapy designed to promote the production of full-length proteins in diseases associated with nonsense mutations.